Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: An extended phase I/II study of the German Testicular Cancer Study Group

Journal of Clinical Oncology

Volumn 21, Issue 22, 2003, Pages 4083-4091

  Schmoll, H J ^a   Kollmannsberger, C ^b   Metzner, B ^b   Hartmann, J T ^b   Schleucher, N ^b   Schoffski P ^b   Schleicher, J ^b   Rick, O ^b   Beyer, J ^b   Hossfeld, D ^b   Kanz, L ^b   Berdel, W E ^b   Andreesen, R ^b   Bokemeyer, C ^b  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE; ICE PROTOCOL 1;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG DOSE SEQUENCE; DRUG FATALITY; DRUG MEGADOSE; FOLLOW UP; GERM CELL TUMOR; GRANULOCYTOPENIA; HUMAN; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TESTIS CANCER; ADOLESCENT; ADULT; AUTOTRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; METASTASIS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; SURVIVAL RATE; TESTIS TUMOR; TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; ETOPOSIDE; GERMINOMA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IFOSFAMIDE; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; TESTICULAR NEOPLASMS; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 0642347620     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.09.035     Document Type: Article

References (34)

1. Einhorn, LH: Treatment of testicular cancer: A new and improved model. J Clin Oncol 8:1777-1781, 1990
2. Bosl GJ, Motzer RJ: Medical progress: Testicular germ-cell cancer. N Engl J Med 337:242-253, 1997
3. Birch R, Williams S, Cone A, et al: Prognostic factors for favorable outcome in disseminated germ cell tumors. J Clin Oncol 4:400-407, 1986
4. International Germ Cell Cancer Collaborative Group: International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15:594-603, 1997
5. Sonneveld DJ, Hoekstra HJ, van der Graaf WT, et al: Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era. Cancer 91:1304-1315, 2001
6. Nichols CR, Williams SD, Loehrer PJ, et al: Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest. Oncology Group protocol. J Clin Oncol 9:1163-1172, 1991
7. Kaye SB, Mead GM, Fossa SD, et al: Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor prognosis metastatic nonseminomatous germ cell tumor: A randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J Clin Oncol 16:692-701, 1998
8. Bower M, Newlands ES, Holden L, et al: Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB/ACE chemotherapy. Ann Oncol 8:477-483, 1997
9. Germa-Lluch JR, Garcia-del-Muro X, Tabernero JM, et al: BOMP/EPI intensive alternating chemotherapy for IGCCC poor-prognosis germ-cell tumors: the Spanish Germ-Cell Cancer Group experience (GG). Ann Oncol 10:289-293, 1999
10. Chevreau C, Droz JP, Pico, JL, et al: Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminomatous germ cell tumours. Preliminary results of a French randomized trial. Eur Urol 23:213-217, 1993
11. Motzer RJ, Mazumdar M, Gulati SC, et al: Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst 85:1828-1835, 1993
12. Motzer RJ, Mazumdar M, Bajorin DF, et al: High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Clin Oncol 15:2546-2552, 1997
13. Decartis MP, Wilkinson P, Welch RS, et al: High-dose chemotherapy and autologous haematopoietic support in poor risk non-seminomatous germ-cell tumors: an effective first-line therapy with minimal toxicity. Ann Oncol 11:427-434, 2000
14. Elias AD, Eder JP, Shea T, et al: High-dose ifosfamide with mesna uroprotection: A phase I study. J Clin Oncol 8:170-178, 1990
15. Wolff SN, Johnson DH, Hainsworth JD, et al: High-dose VP-16-213 monotherapy for refractory germinal malignancies: A phase II study. J Clin Oncol 2:271-274, 1984
16. Nichols CR, Tricot G, Williams SD, et al: Dose-intensive chemotherapy in refractory germ cell cancer-a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 7:932-939, 1989
17. Siegert W, Beyer J, Strohscheer I, et al: High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: A phase I/1I study. J Clin Oncol 12:1223-1231, 1994
18. Bokemeyer C, Schmoll H-J, Harstrick A, et al: A phase I/II study of a stepwise dose-escalated regimen of cisplatin, etoposide and ifosfamide plus granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced germ cell tumours. Eur J Cancer 29A:2225-2231, 1993
19. Bokemeyer C, Harstrick A, Beyer J, et al: The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group. Semin Oncol 25:24-32, 1998
20. Kanz L, Brugger W, Mertelsmann R: Haematopoietic growth factors and peripheral blood stem cells as supportive agents in dose intensification. Eur J Cancer 29A:S23-26, 1993 (suppl 5)
21. Kollmannsberger C, Nichols C, Bamberg M, et al: First-line high-dose chemotherapy +/- radiation therapy in patients with metastatic germ-cell cancer and brain metastases. Ann Oncol 11:553-559, 2000
22. Miller AB, Hoodgstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-211, 1981
23. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
24. Ozols RF, Ihde DC, Linehan WM, et al: A randomized trial of standard chemotherapy versus a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors. J Clin Oncol 6:1031-1040, 1988
25. Nichols CR, Roth BJ, Broun ER, et al: Dose intensity in germ cell cancer: continued lessons from a model neoplasm. Eur Urol 23:231-238, 1993
26. Husband DJ, Green JA: POMB/ACE chemotherapy in non-seminomatous germ cell tumours: outcome and importance of dose intensity. Eur J Cancer 28:86-91, 1992
27. Fizazi K, Zelek L: Is one cycle every three or four weeks' obsolete? A critical review of dose-dense chemotherapy in solid neoplasms. Ann Oncol 11:133-149, 2000
28. Ozols RF: Cisplatin dose intensity. Semin Oncol 16:22-30, 1989
29. Bhatia S, Abonour R, Porcu P, et al: High-dose chemotherapy as initial salvage-chemotherapy in patients with relapsed testicular cancer. J Clin Oncol 18:3346-3351, 2000
30. Bokemeyer C, Berger CC, Kuczyk MA, et al: Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol 14:2923-2932, 1996
31. Williams SD, Birch R, Einhorn LH, et al: Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316:1435-1440, 1987
32. Hamilton CR, Bliss JM, and Horwich A: The late effects of cis-platinum on renal function. Eur J Cancer Clin Oncol 25:185-189, 1989
33. Kollmannsberger C, Beyer J, Droz JP, et al: Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. J Clin Oncol 16:3386-3391, 1998
34. Bokemeyer C, Kollmannsberger C, Meisner C, et al: First-line high-dose chemotherapy compared to standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched pair analysis. J Clin Oncol 17:3450-3456, 1999